相似文献
1
Advances in the Treatment of Hepatitis B and Hepatitis C Nonresponders: A Report of Symposia Presented at the 15th Conference of the Asian Pacific Association for the Study of the LiverAugust 18-21, 2005Bali, Indonesia.
Gastroenterol Hepatol (N Y). 2006 Jan;2(1 Suppl 1):1-16.
2
Association between chronic hepatitis B virus infection and diabetes among Asian Americans and Pacific Islanders.
Dig Liver Dis. 2007 Jun;39(6):549-56. doi: 10.1016/j.dld.2007.02.014. Epub 2007 Apr 9.
3
The declining prevalence of hepatitis B virus infection among Asian and Pacific Islander children.
Asian Am Pac Isl J Health. 2001 Summer-Fall;9(2):162-78.
4
ASVAC2022 : 8 Asian Vaccine Conference.
Hum Vaccin Immunother. 2023 Dec 31;19(1):2165360. doi: 10.1080/21645515.2023.2165360. Epub 2023 Jan 19.
5
Report of the online meeting of the 7th Asian Conference on Environmental Mutagens (ACEM), China, November 5-6, 2022.
Genes Environ. 2023 Feb 7;45(1):6. doi: 10.1186/s41021-023-00263-8.
6
China's efforts to shed its title of "Leader in liver disease".
Drug Discov Ther. 2007 Oct;1(2):84-5.
7
Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma.
Hepatol Int. 2010 Mar 18;4(2):439-74. doi: 10.1007/s12072-010-9165-7.
8
9
Report of the survey of hepatitis antigens in the Asian-Pacific region.
Ann Acad Med Singap. 1980 Apr;9(2):133-5.
10
Liver carcinoma prevention among Asian Pacific Islanders. Getting hepatitis B shots into arms.
Cancer. 2001 Jan 1;91(1 Suppl):252-6. doi: 10.1002/1097-0142(20010101)91:1+<252::aid-cncr14>3.0.co;2-y.
本文引用的文献
1
Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.
N Engl J Med. 2005 Jun 30;352(26):2682-95. doi: 10.1056/NEJMoa043470.
2
The efficacy and safety of thymosin alpha-1 in Japanese patients with chronic hepatitis B; results from a randomized clinical trial.
J Viral Hepat. 2005 May;12(3):300-6. doi: 10.1111/j.1365-2893.2005.00633.x.
3
Immunology of hepatitis B virus and hepatitis C virus infection.
Nat Rev Immunol. 2005 Mar;5(3):215-29. doi: 10.1038/nri1573.
4
Viral hepatitis in minority America.
J Clin Gastroenterol. 2005 Feb;39(2):144-51.
5
Combination therapy of thymalfasin (thymosin-alpha 1) and peginterferon alfa-2a in patients with chronic hepatitis C virus infection who are non-responders to standard treatment.
J Gastroenterol Hepatol. 2004 Dec;19(12):S76-8.
6
Thymalfasin: an immune system enhancer for the treatment of liver disease.
J Gastroenterol Hepatol. 2004 Dec;19(12):S69-72.
7
Thymalfasin for the treatment of chronic hepatitis B.
Expert Rev Anti Infect Ther. 2004 Feb;2(1):9-16. doi: 10.1586/14787210.2.1.9.
8
Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures.
J Viral Hepat. 2004 Mar;11(2):97-107. doi: 10.1046/j.1365-2893.2003.00487.x.
9
Long-term safety of lamivudine treatment in patients with chronic hepatitis B.
Gastroenterology. 2003 Dec;125(6):1714-22. doi: 10.1053/j.gastro.2003.09.033.
10
Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients.
Hepatology. 2003 Dec;38(6):1419-27. doi: 10.1016/j.hep.2003.09.040.
Zotero 插件